Zafgen (ZFGN) Investor Presentation - Slideshow

ZGN-1061 for Type 2 Diabetes and NASH - ZGN-1061 Phase 2 proof-of-concept trial demonstrated statistically significant A1C lowering efficacy and weight loss, with a safety and tolerability profile generally comparable to placebo[3] - In the proof-of-concept trial, the 1.8 mg dose of ZGN-1061 showed a statistically significant improvement in A1C compared to placebo (p<0.0001)[6, 7] - The 1.8 mg dose of ZGN-1061 also showed a statistically significant improvement in weight compared to placebo (p<0.0001)[8] - Nonclinical studies of ZGN-1061 have demonstrated significant NASH model efficacy, and complementary efficacy in combination with a GLP-1[3] - Plasma ALT decreased by 25% and 44% in 0.06 mg/kg and 0.3 mg/kg ZGN-1061 groups respectively in NASH nonclinical study[10] ZGN-1258 for Prader-Willi Syndrome - Development plans for ZGN-1258 were suspended due to an unexpected finding in long-term toxicology studies[4] - Prader-Willi syndrome affects approximately 200,000 patients worldwide[18] - Over 400 participants enrolled in PATH for PWS natural history study as of March 2019[20] ZGN-1345 for Metabolic Liver Disease - ZGN-1345 was named as a development candidate in 4Q 2018[4] - ZGN-1345 is an orally dosed MetAP2i with high liver concentrations but minimal-to-no detectable systemic exposure; once daily dosing expected[4, 21] Financial Status - As of December 31, 2018, the company had a cash position of $118 million, expected to extend through at least 2020[4] Type 2 Diabetes Market - There are 415 million people worldwide living with type 2 diabetes, expected to grow to 642 million by 2040[5] - Over 50% of patients with type 2 diabetes have uncontrolled A1C, despite multiple approved treatments available[5]